Trial Profile

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 23 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Laroprovstat (Primary)
Indications Angina pectoris; Cardiovascular disorders; Ischaemic stroke; Myocardial infarction; Peripheral arterial disorders
Focus Registrational; Therapeutic Use
Acronyms AZURE-LDL
Sponsors AstraZeneca

20 Jan 2026 Planned End Date changed from 24 Mar 2027 to 11 Jan 2027.
20 Jan 2026 Planned primary completion date changed from 24 Mar 2027 to 11 Jan 2027.
20 Jan 2026 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com